Pelthos Therapeutics Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Pelthos Therapeutics Inc. (PTHS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.10 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2025-08-13
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $2.40M.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $706.48K, a 676.40% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-12-31 was $620.98K, a 34.96% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-09-30 was $2.04M, a 229.58% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.18M, a 27.56% decline from fiscal 2023.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.63M, a 293.37% increase from fiscal 2022.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $413.60K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2025-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.10M 10-Q · filed 2025-08-13 | $3.72M derived: sum of 3 quarters · filed 2025-08-13 | $5.76M derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | $706.48K 10-Q · filed 2025-05-13 | $1.33M derived: sum of 2 quarters · filed 2025-05-13 | $3.37M derived: sum of 3 quarters · filed 2025-05-13 | $1.79M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-12-31 | $620.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.66M derived: sum of 2 quarters · filed 2025-03-27 | $1.09M derived: sum of 3 quarters · filed 2025-08-13 | $1.18M 10-K · filed 2025-03-27 |
| 2024-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $466.60K derived: sum of 2 quarters · filed 2025-08-13 | $557.59K 10-Q · filed 2024-11-13 | $1.02M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.48M 10-Q · filed 2025-08-13 | -$1.02M derived: sum of 3 quarters · filed 2025-08-13 | -$402.40K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $90.99K 10-Q · filed 2025-05-13 | $551.12K derived: sum of 2 quarters · filed 2025-05-13 | $1.17M derived: sum of 3 quarters · filed 2025-05-13 | $1.35M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $460.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.08M derived: sum of 2 quarters · filed 2025-03-27 | $1.26M derived: sum of 3 quarters · filed 2025-03-27 | $1.63M 10-K · filed 2025-03-27 |
| 2023-09-30 | $618.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $799.55K derived: sum of 2 quarters · filed 2024-11-13 | $1.17M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $180.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $548.30K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $367.33K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $413.60K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |